Sensus Healthcare Reports Third Quarter 2025 Financial Results Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of

Sensus Healthcare Reports Third Quarter 2025 Financial Results

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (November 6, 2025) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly

effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions,

announces financial results for the three and nine months ended September 30, 2025.

of the third quarter of 2025 and subsequent weeks include the following:

this week, CMS published first-ever dedicated CPT codes for SRT that represents compelling economics and reimbursement certainty.

These new codes narrow the gap between office-based reimbursement and hospital outpatient rates, and by leveling the playing field, they

enable strengthening adoption for SRT," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "We

are extremely excited for our physician partners and customers, and especially for their patients, as this is clear validation of our

SRT technology for treating non-melanoma skin cancer and keloids for years to come, supported by strong reimbursement. Internationally,

we are laying groundwork for broader expansion following our MDSAP certification and are seeing strong interest across select markets."

the third quarter, we continued to execute on our strategic priorities and made progress in several areas across the business,"

added Mr. Sardano. "We shipped 16 SRT systems, including three to China, and saw healthy utilization trends within our Fair Deal

Agreement program. FDA treatment volumes were up 20% over the second quarter and up 52% compared with the first quarter, underscoring

the ongoing adoption among installed sites and the growing awareness of SRT and IG-SRT among patients and providers. We exited the quarter

with $24.5 million in cash and no debt. Importantly, with nearly 100 systems in inventory, we are well positioned to respond quickly

"In September we announced the publication of

new clinical findings demonstrating that SRT offers significant benefit when combined with punch excision to treat keloids. This study

is one of very few to examine punch excision debulking with SRT, and the findings reinforce SRT's versatility and medical relevance

beyond aesthetics, helping further validate our technology's growing utility across multiple indications and procedures,"

concluded Mr. Sardano.

Quarter Financial Results

were $6.9 million for the third quarter of 2025 compared to $8.8 million for the third quarter of 2024, a decrease of $1.9 million,

or 21.6%. The number of units sold in the third quarter of 2025 was 16 compared to 27 in the third quarter of 2024. The decrease

in revenue was primarily driven by a lower number of units sold to a large customer in the third quarter of 2025 compared to the

third quarter of 2024, slightly offset by revenue recognized from the new placement program under the Fair Deal Agreement.

Cost of sales was $4.2 million for the third quarter of 2025 compared with $3.6 million for the third quarter of 2024. The increase

was primarily related to higher costs of servicing systems and the cost associated with the new placement program compared with

the prior-year period.

profit was $2.7 million for the third quarter of 2025 compared with $5.2 million for the third quarter of 2024. Gross margin was

39.1% in the third quarter of 2025 compared with 59.1% in the corresponding period in 2024. The decreases were primarily driven

by lower sales, higher costs of servicing systems and the cost associated with the new placement program.

General and administrative expense was $1.9 million for the third quarter of 2025 compared with $1.6 million for the third quarter

of 2024, with the increase reflecting higher IT and professional services fees and compensation.

Selling and marketing expense was $1.5 million for the third quarter of 2025 compared with $1.3 million for the third quarter

of 2024, with the increase reflecting higher headcount and payroll costs due to commissions related to the new placement program.

and development expense was $1.8 million for the third quarter of 2025 compared with $0.9 million for the third quarter of 2024,

with the increase reflecting significant lobbying costs related to billing code reimbursement, higher headcount and an increase

in product development costs related to next-generation systems.

income of $0.2 million for the third quarter of 2025 and $0.3 million for the third quarter of 2024 was related primarily to interest

loss for the third quarter of 2025 was $0.9 million, or $0.06 per share, compared with net income of $1.2 million, or $0.07 per

diluted share, for the third quarter of 2024.

EBITDA for the third quarter of 2025 was negative $2.4 million compared with positive $1.6 million for the third quarter of 2024.

Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation

expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reason these non-GAAP financial

measures are provided.

and cash equivalents were $24.5 million as of September 30, 2025, compared with $22.1 million as of December 31, 2024. The Company

had no outstanding borrowings under its revolving line of credit at the end of either period.

Month Financial Results

were $22.5 million for the first nine months of 2025 compared to $28.7 million for the first nine months of 2024, a decrease of

$6.2 million, or 21.6%. The number of units sold in the first nine months of 2025 was 56 compared to 76 in the first nine months

of 2024. The decrease in revenue was primarily driven by a lower number of units sold to a large customer, slightly offset by

revenue recognized from the new placement program under the Fair Deal Agreement in the 2025 period.

of sales was $12.6 million for the first nine months of 2025 compared with $11.4 million for the same period in 2024. The increase

was primarily related to higher costs of servicing systems and the cost associated with the new placement program in the 2025

profit was $10.0 million for the first nine months of 2025 compared with $17.3 million for the same period in 2024. Gross margin

was 44.4% in the first nine months of 2025 compared with 60.3% in the corresponding period in 2024. The decreases were primarily

driven by lower sales, higher costs of servicing systems and the cost associated with the new placement program in the 2025 period.

and administrative expense was $6.1 million for the first nine months of 2025 compared with $4.7 million for the same period in

2024. The increase was primarily due to higher professional fees and insurance cost.

and marketing expense was $5.1 million for the first nine months of 2025 compared with $3.6 million for the same period in 2024.

The increase was primarily driven by an increase in tradeshow costs, payroll cost due to commissions related to the new placement

program, and an increase in headcount.

and development expense was $5.9 million for the first nine months of 2025 compared with $2.7 million for the same period in 2024.

The increase was primarily due to significant lobbying costs related to billing code reimbursement, higher headcount and an increase

in product development costs related to next-generation systems.

income of $0.5 million for the first nine months of 2025 and $0.7 million for the same period in 2024 relates primarily to interest

Net loss for the first nine months of 2025 was $4.6 million, or $0.28 per

share, compared with net income of $5.1 million, or $0.31 per diluted share, for the first nine months of 2024.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure,

in its analysis of the Company's performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures,

nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation

of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense,

provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare.

Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from

those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists

investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure

underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the

TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management

will discuss these financial results, provide a business update and answer questions.

are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the

live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register

can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask

the operator to be connected to the Sensus Healthcare conference call.

call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company's

website at www.sensushealthcare.com.

the conclusion of the conference call, a telephone replay will be available until December 6th by dialing 877-344-7529

(U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International). At the system prompt, enter the replay code

5165150. An archived webcast will be available in the Investor Relations section of the Company's website for a period of

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly

effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare

offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.